{"entity":{"id":"kevin-kalinsky","kind":"person","name":"Kevin Kalinsky","aka":[],"tldr":"Led RxPONDER, which showed postmenopausal women with 1-3 positive nodes and low recurrence scores do not need chemotherapy.","summary":"Kevin Kalinsky was principal investigator of SWOG S1007 (RxPONDER), which extended the TAILORx result to node-positive disease: postmenopausal women with one to three positive nodes and a recurrence score of 25 or less gained nothing from chemotherapy, while premenopausal women did. He directs breast oncology at Winship and leads SWOG breast trials on ctDNA-guided escalation.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kalinsky%20K%5BAuthor%5D%20RxPONDER"}],"tags":["breast","de-escalation","swog"],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["oncotype-dx"],"companies":[],"institutions":["emory-winship"],"pathways":[],"terms":[],"trials":["rxponder"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Glenn Family Breast Center, Winship Cancer Institute of Emory University","institutionId":"emory-winship","specialisms":["Breast cancer","Genomic assays","Node-positive disease","SWOG trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kalinsky%20K%5BAuthor%5D%20RxPONDER"}],"papers":[{"title":"21-gene assay to inform chemotherapy benefit in node-positive breast cancer (RxPONDER)","journal":"NEJM","year":2021,"doi":"10.1056/NEJMoa2108873"},{"title":"Randomized phase II trial of endocrine therapy with or without ribociclib after neoadjuvant chemotherapy in HR-positive breast cancer (NeoPAL and related studies)","journal":"Clinical Cancer Research","year":2020}],"orcid":"0000-0002-3113-7902"},"route":"/people/kevin-kalinsky/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"drug":[{"id":"oncotype-dx","kind":"drug","name":"Oncotype DX","route":"/drugs/oncotype-dx/"}],"institution":[{"id":"emory-winship","kind":"institution","name":"Winship Cancer Institute of Emory University","route":"/institutions/emory-winship/"}],"trial":[{"id":"rxponder","kind":"trial","name":"RxPONDER (SWOG S1007)","route":"/trials/rxponder/"}],"paper":[{"id":"paper-bardia-ascent-trop2-biomarker-ann-oncol-2021","kind":"paper","name":"Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer","route":"/key-papers/paper-bardia-ascent-trop2-biomarker-ann-oncol-2021/"}]}}